Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Temozolomide is an oral alkylating agent that is used as the first line treatment for glioblastoma multiform, and in recurrent anaplastic astrocytoma, as well as having demonstrable activity in patients with metastatic melanoma. However, as the case with other chemotherapeutic agents, the development of resistance often limits the therapeutic benefit of temozolomide, particularly in the case of glioblastoma. A number of resistance mechanisms have been proposed including the development of cytoprotective autophagy. Cytoprotective autophagy is a survival mechanism that confers upon tumor cells the ability to survive in a nutrient deficient environment as well as under external stresses, such as cancer chemotherapeutic drugs and radiation, in part through the suppression of apoptotic cell death. In this review/commentary, we explore the available literature and provide an overview of the evidence for the promotion of protective autophagy in response to temozolomide, highlighting the possibility of targeting autophagy as an adjuvant therapy to potentially increase the effectiveness of temozolomide and to overcome the development of resistance.
Funding Information
  • National Cancer Institute/National Institutes of Health (CA268819, CA239706, W81XWH 19-1-0490)
  • Department of Defense Congressionally Directed Breast Cancer Research Program (CA268819, CA239706, W81XWH 19-1-0490)

This publication has 92 references indexed in Scilit: